Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer.

Liwei LangFang WangZhichun DingXiangdong ZhaoReid LovelessJin XieChloe ShayPeng QiuYonggang KeNabil F SabaYong Teng

Published in: Journal of experimental & clinical cancer research : CR (2021)

These findings uncover the critical role of GLS1-mediated glutaminolysis in CPI-613 treatment and suggest that the CB-839 and CPI-613 combination may potentiate synergistic anticancer activity for HNSCC therapeutic gain.

Keyphrases

cancer therapy
replacement therapy